This result, in complete accordance with our data, showed an over-expression of IDO1 and an under-expression of AKR1C3 in responders patients (Supplemental figure 3) according to Residual tumor classification (see Methods paragraph), confirming the same trend obtained in our study [28]. The gene discussed is AKR1C3; the disease is neoplasm.